Pasar al contenido principal

TRAYECTORIAS DE SALUD Y EL PAPEL DEL SEXO, GENERO, ENVEJECIMIENTO, Y TRATAMIENTOS EN EL DESARROLLO DE COMORBILIDADES

PID2022-141809OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario BARCELONA SUPERCOMPUTING CENTER CENTRO NACIONAL DE SUPERCOMPUTACION

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

UPCommons. Portal del coneixement obert de la UPC
Publicación Artículo científico (JournalArticle)

Prevalence and differences in the co-administration of drugs known to interact: an analysis of three distinct and large populations

  • Sánchez, Jon|||0000-0001-7959-6326
  • Brattig Correia, Rion
  • Camacho Artacho, Marta
  • Lepore, Rosalba
  • Mattos, Mauro M.
  • Rocha, Luis M.
  • Valencia, Alfonso|||0000-0002-8937-6789
Background The co-administration of drugs known to interact greatly impacts morbidity, mortality, and health economics. This study aims to examine the drug–drug interaction (DDI) phenomenon with a large-scale longitudinal analysis of age and gender differences found in drug administration data from three distinct healthcare systems. Methods This study analyzes drug administrations from population-wide electronic health records in Blumenau (Brazil; 133 K individuals), Catalonia (Spain; 5.5 M individuals), and Indianapolis (USA; 264 K individuals). The stratified prevalences of DDI for multiple severity levels per patient gender and age at the time of administration are computed, and null models are used to estimate the expected impact of polypharmacy on DDI prevalence. Finally, to study actionable strategies to reduce DDI prevalence, alternative polypharmacy regimens using drugs with fewer known interactions are simulated. Results A large prevalence of co-administration of drugs known to interact is found in all populations, affecting 12.51%, 12.12%, and 10.06% of individuals in Blumenau, Indianapolis, and Catalonia, respectively. Despite very different healthcare systems and drug availability, the increasing prevalence of DDI as patients age is very similar across all three populations and is not explained solely by higher co-administration rates in the elderly. In general, the prevalence of DDI is significantly higher in women — with the exception of men over 50 years old in Indianapolis. Finally, we show that using proton pump inhibitor alternatives to omeprazole (the drug involved in more co-administrations in Catalonia and Blumenau), the proportion of patients that are administered known DDI can be reduced by up to 21% in both Blumenau and Catalonia and 2% in Indianapolis. Conclusions DDI administration has a high incidence in society, regardless of geographic, population, and healthcare management differences. Although DDI prevalence increases with age, our analysis points to a complex phenomenon that is much more prevalent than expected, suggesting comorbidities as key drivers of the increase. Furthermore, the gender differences observed in most age groups across populations are concerning in regard to gender equity in healthcare. Finally, our study exemplifies how electronic health records’ analysis can lead to actionable interventions that significantly reduce the administration of known DDI and its associated human and economic costs., J.S.V. was funded by the Spanish Ministry of Economics and Competitiveness (RTI2018-096653-B-I00 and PID2022-141809OB-I00). R.B.C. was partially funded by Fundacão para a Ciência e a Tecnologia (grant PTDC/MECAND/30221/2017) and the National Institutes of Health (NIH), National Library of Medicine (grant R01-LM012832). L.M.R. was partially funded by the National Institutes of Health (NIH), National Library of Medicine (grants R01-LM011945 and R01-LM012832), by a Fulbright Commission fellowship, and by the National Science Foundation Research Traineeship “Interdisciplinary Training in Complex Networks and Systems” (grant 1735095). J.S.V., R.B.C., and L.M.R. were funded by the Fundação para a Ciência e a Tecnologia Grant No. 2022.09122.PTDC (https://doi.org/https://doi.org/10.54499/2022.09122.PTDC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., Peer Reviewed
UPCommons. Portal del coneixement obert de la UPC
Publicación Artículo científico (JournalArticle)

Patient stratification reveals the molecular basis of disease co-occurrences

  • Urda García, Beatriz
  • Sánchez Valle, Jon
  • Lepore, Rosalba
  • Valencia, Alfonso|||0000-0002-8937-6789
Epidemiological evidence shows that some diseases tend to co-occur; more exactly, certain groups of patients with a given disease are at a higher risk of developing a specific secondary condition. Here, we develop an approach to generate a disease network that uses the accumulating RNA-seq data on human diseases to significantly match an unprecedented proportion of known comorbidities, providing plausible biological models for such co-occurrences and effectively mirroring the underlying structure of complex disease relationships. Furthermore, 64% of the known disease pairs can be explained by analyzing groups of patients with similar expression profiles, highlighting the importance of patient stratification in the study of comorbidities. These results solidly support the existence of molecular mechanisms behind many of the known comorbidities, with most captured co-occurrences implicating the immune system. Additionally, we identified new and potentially underdiagnosed comorbidities, providing molecular insights that could inform targeted therapeutic strategies. We provide a functional and comprehensive resource to explore diseases, disease co-occurrences, and their underlying molecular processes at different resolution levels at http://disease-perception.bsc.es/rgenexcom/., This work has been supported by the Grants PRE2019-090454 and BES-2016-077403, both funded by MICIU/AEI/10.13039/501100011033 and by “ESF Investing in your future”; and the Grants RTI2018-096653-B-I00 and PID2022-141809OB-I00, both funded by MICIU/AEI/10.13039/501100011033 and by “ERDF/EU”, by the “European Union.” The research leading to these results has received funding from the European Community’s Horizon Europe Programme under Grant agreement No. 101136957 (COMMUTE). We would like to thank Davide Cirillo for their helpful comments on the work.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Patient stratification reveals the molecular basis of disease co-occurrences

  • Urda García, Beatriz
  • Sánchez Valle, Jon
  • Lepore, Rosalba
  • Valencia, Alfonso
Epidemiological evidence shows that some diseases tend to co-occur; more exactly, certain groups of patients with a given disease are at a higher risk of developing a specific secondary condition. Here, we develop an approach to generate a disease network that uses the accumulating RNA-seq data on human diseases to significantly match an unprecedented proportion of known comorbidities, providing plausible biological models for such co-occurrences and effectively mirroring the underlying structure of complex disease relationships. Furthermore, 64% of the known disease pairs can be explained by analyzing groups of patients with similar expression profiles, highlighting the importance of patient stratification in the study of comorbidities. These results solidly support the existence of molecular mechanisms behind many of the known comorbidities, with most captured co-occurrences implicating the immune system. Additionally, we identified new and potentially underdiagnosed comorbidities, providing molecular insights that could inform targeted therapeutic strategies. We provide a functional and comprehensive resource to explore diseases, disease co-occurrences, and their underlying molecular processes at different resolution levels at http://disease-perception.bsc.es/rgenexcom/., This work has been supported by the Grants PRE2019-090454 and BES-2016-077403, both funded by MICIU/AEI/10.13039/501100011033 and by “ESF Investing in your future”; and the Grants RTI2018-096653-B-I00 and PID2022-141809OB-I00, both funded by MICIU/AEI/10.13039/501100011033 and by “ERDF/EU”, by the “European Union.” The research leading to these results has received funding from the European Community’s Horizon Europe Programme under Grant agreement No. 101136957 (COMMUTE). We would like to thank Davide Cirillo for their helpful comments on the work., Postprint (published version)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Prevalence and differences in the co-administration of drugs known to interact: an analysis of three distinct and large populations

  • Sánchez, Jon
  • Brattig Correia, Rion
  • Camacho Artacho, Marta
  • Lepore, Rosalba
  • Mattos, Mauro M.
  • Rocha, Luis M.
  • Valencia, Alfonso
Background The co-administration of drugs known to interact greatly impacts morbidity, mortality, and health economics. This study aims to examine the drug–drug interaction (DDI) phenomenon with a large-scale longitudinal analysis of age and gender differences found in drug administration data from three distinct healthcare systems. Methods This study analyzes drug administrations from population-wide electronic health records in Blumenau (Brazil; 133 K individuals), Catalonia (Spain; 5.5 M individuals), and Indianapolis (USA; 264 K individuals). The stratified prevalences of DDI for multiple severity levels per patient gender and age at the time of administration are computed, and null models are used to estimate the expected impact of polypharmacy on DDI prevalence. Finally, to study actionable strategies to reduce DDI prevalence, alternative polypharmacy regimens using drugs with fewer known interactions are simulated. Results A large prevalence of co-administration of drugs known to interact is found in all populations, affecting 12.51%, 12.12%, and 10.06% of individuals in Blumenau, Indianapolis, and Catalonia, respectively. Despite very different healthcare systems and drug availability, the increasing prevalence of DDI as patients age is very similar across all three populations and is not explained solely by higher co-administration rates in the elderly. In general, the prevalence of DDI is significantly higher in women — with the exception of men over 50 years old in Indianapolis. Finally, we show that using proton pump inhibitor alternatives to omeprazole (the drug involved in more co-administrations in Catalonia and Blumenau), the proportion of patients that are administered known DDI can be reduced by up to 21% in both Blumenau and Catalonia and 2% in Indianapolis. Conclusions DDI administration has a high incidence in society, regardless of geographic, population, and healthcare management differences. Although DDI prevalence increases with age, our analysis points to a complex phenomenon that is much more prevalent than expected, suggesting comorbidities as key drivers of the increase. Furthermore, the gender differences observed in most age groups across populations are concerning in regard to gender equity in healthcare. Finally, our study exemplifies how electronic health records’ analysis can lead to actionable interventions that significantly reduce the administration of known DDI and its associated human and economic costs., J.S.V. was funded by the Spanish Ministry of Economics and Competitiveness (RTI2018-096653-B-I00 and PID2022-141809OB-I00). R.B.C. was partially funded by Fundacão para a Ciência e a Tecnologia (grant PTDC/MECAND/30221/2017) and the National Institutes of Health (NIH), National Library of Medicine (grant R01-LM012832). L.M.R. was partially funded by the National Institutes of Health (NIH), National Library of Medicine (grants R01-LM011945 and R01-LM012832), by a Fulbright Commission fellowship, and by the National Science Foundation Research Traineeship “Interdisciplinary Training in Complex Networks and Systems” (grant 1735095). J.S.V., R.B.C., and L.M.R. were funded by the Fundação para a Ciência e a Tecnologia Grant No. 2022.09122.PTDC (https://doi.org/https://doi.org/10.54499/2022.09122.PTDC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., Peer Reviewed, Postprint (published version)